COMMUNIQUÉS West-GlobeNewswire

KFSHRC Pioneering Ethical Innovation in Global Healthcare
13/09/2024
RIYADH, Saudi Arabia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has reiterated its commitment to ethical innovation in its efforts to champion medical research and [...]
MetasTx Welcomes Esteemed Cancer Scientist Dr. Jonathan Chernoff to the Board of Managers
13/09/2024
Renowned Cancer Researcher Brings Deep Expertise to Accelerate MetasTx’s Mission to Combat Metastatic Cancer PHILADELPHIA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- MetasTx , a pioneering biopharmaceutical company dedicated to [...]
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
13/09/2024
Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN [...]
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
13/09/2024
PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global [...]
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
13/09/2024
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare [...]
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
13/09/2024
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin [...]
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
13/09/2024
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12/09/2024
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve [...]
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield
12/09/2024
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
12/09/2024
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]
OneMedNet Announces Receipt of Nasdaq Notices Regarding Delayed Forms 10-Q
12/09/2024
MINNEAPOLIS, Sept. 12, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health [...]
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
12/09/2024
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, [...]
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
12/09/2024
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference
12/09/2024
CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced [...]
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
12/09/2024
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
12/09/2024
Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces its intention to issue, subject to market [...]
Valneva annonce le lancement d’un projet d’augmentation de capital d’environ 60 millions d’euros
12/09/2024
Saint-Herblain (France), 12 septembre 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) ( « Valneva » ou la « Société » ), société spécialisée dans les vaccins, annonce aujourd’hui, sous réserve des conditions de [...]
Immunocore to present at the 2024 Cantor Global Healthcare Conference
12/09/2024
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or [...]
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12/09/2024
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate [...]

Pages